RESUMO
OBJECTIVES: Early treatment of HIV-1 infection at all CD4 levels has demonstrated clinical and public health benefits. This analysis examined the costs, health outcomes, and cost-effectiveness of increased HIV-1 screening and early treatment initiation in the UK. METHODS: A Markov model followed theoretical cohorts of men who have sex with men (MSM), heterosexuals, and people who inject drugs (PWID) with initially undiagnosed HIV-1 infection over their remaining lifetimes. The analysis examined increased HIV-1 screening (resulting in 10-50% improvements in diagnosis rates) versus current screening in sexual health services (SHS) and other settings, with all individuals initiating treatment within 3 months of diagnosis. Health status was modelled by viral load and CD4 cell count as individuals progressed to diagnosis and treatment. Individuals accrued quality-adjusted life-years (QALYs), incurred costs for screening and HIV-related clinical management, and were at risk of transmitting HIV-1 infection to their partners. Input parameter data were taken primarily from UK-specific published sources. All outcomes were discounted at 3.5% annually. RESULTS: The model estimated that increased screening and early treatment resulted in fewer onward HIV transmissions, more QALYs, and higher total costs. For SHS, incremental cost-effectiveness ratios (ICERs) for heterosexuals (~£22 000/QALY gained) were within typical UK willingness-to-pay thresholds and were well below these thresholds for MSM (~£9500/QALY gained) and PWID (~£6500/QALY gained). Sensitivity analysis showed that model results were robust. CONCLUSIONS: Increased HIV-1 screening and early treatment initiation may be a cost-effective strategy to reduce HIV transmission and improve health for MSM, heterosexuals, and PWID in the UK.
Assuntos
Infecções por HIV , HIV-1 , Custos de Cuidados de Saúde , Programas de Rastreamento/economia , Adulto , Análise Custo-Benefício , Feminino , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Humanos , Masculino , Cadeias de Markov , Pessoa de Meia-Idade , Saúde Pública , Anos de Vida Ajustados por Qualidade de Vida , Reino UnidoRESUMO
Heterozygosity for a mutant dysfunctional C1 inhibitor protein, a member of the serine proteinase inhibitor (serpin) superfamily, results in type II hereditary angioneurotic oedema. We identified a "hinge" region mutation in C1 inhibitor with a Val to Glu replacement at P14 Val-432. Recombinant C1 inhibitors P10 Ala-->Thr and P14Val-->Glu did not form stable complexes with fluid phase C1s or kallikrein. The P14 Val-->Glu mutant, however, was cleaved to a 96K form by C1s, while the P10 Ala-->Thr mutant was not. The recombinant P10 mutant also did not complex with C1s, kallikrein or beta-factor Xlla-Sepharose. The two mutations, therefore, result in dysfunction by different mechanisms: in one (P14 Val-->Glu), the inhibitor is converted to a substrate, while in the other (P10 Ala-->Thr), interaction with target protease is blocked.
Assuntos
Angioedema/genética , Proteínas Inativadoras do Complemento 1/genética , Mutação Puntual , Alanina , Sequência de Aminoácidos , Angioedema/sangue , Animais , Sequência de Bases , Linhagem Celular , Células Cultivadas , Códon/genética , Proteínas Inativadoras do Complemento 1/química , Proteínas Inativadoras do Complemento 1/metabolismo , Complemento C1s/metabolismo , Fibroblastos/metabolismo , Glutamatos , Ácido Glutâmico , Heterozigoto , Humanos , Calicreínas/metabolismo , Dados de Sequência Molecular , Estrutura Secundária de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Treonina , Transfecção , ValinaRESUMO
Synthetic peptides that correspond to the COOH-terminal portion of C2b enhance vascular permeability in human and guinea pig skin. In human studies, 1 nmol of the most active peptide of 25-amino acid residues produced substantial local edema. A pentapeptide and a heptapeptide corresponding to the COOH-terminal sequence of C2b each induced contraction of estrous rat uterus in the micromole range; a peptide of 25 amino acids from this region induced a like contraction of rat uterus at a concentration 20-fold lower than the smaller peptides. The vascular permeability of guinea pig skin was enhanced by doses of these synthetic peptides in a similar fashion as that observed for the concentration of rat uterus. The induction of localized edema by intradermal injection in both the guinea pig and the human proceeds in the presence of antihistaminic drugs, suggesting that there is a histamine-independent component to the observed increase in vascular permeability. Cleavage of C2 with the enzymic subcomponent of C1, C1s, yields only C2a and C2b, and no small peptides, whereas cleavage of C2 with C1s and plasmin yields a set of small peptides. These plasmin-cleaved peptides are derived from the COOH terminus of C2b, and they induce the contraction of estrous rat uterus.
Assuntos
Angioedema/etiologia , Complemento C2/fisiologia , Sequência de Aminoácidos , Angioedema/imunologia , Bioensaio , Permeabilidade Capilar/efeitos dos fármacos , Complemento C1s/metabolismo , Complemento C2/isolamento & purificação , Fibrinolisina/metabolismo , Humanos , Dados de Sequência Molecular , Contração Muscular/efeitos dos fármacos , Peptídeos/síntese química , Peptídeos/farmacologia , Relação Estrutura-AtividadeRESUMO
Synergistic cytotoxicity is a term used to describe a cytotoxic system in which xenogeneic erythrocyte target cells are lysed in the presence of nonimmune human mononuclear effector cells and antibody-depleted normal human serum. Neither the mononuclear cells nor the serum alone are cytolytic to the target erythrocytes. Previous studies have shown that the serum activity is not immunoglobulin and is heat-labile, suggesting a similarity to serum complement. In this report, sera deficient in various complement components as well as highly purified single complement components were tested with whole mononuclear cell populations and purified monocytes and lymphocytes to further characterize this cytotoxicity system. Whole mononuclear cell populations failed to mediate target cell lysis in sera deficient in C5 or factor B. However, C3-deficient serum, even in the presence of anti-C3 antibody, supported synergistic cytotoxicity normally. Purified lymphocytes were also normally cytotoxic in C3-deficient serum but failed to lyse targets in sera deficient in C5, C7, C8, or depleted of factor B. Purified monocytes failed to lyse the target cells only in factor B-depleted serum and could lyse the target cells in serum-free medium when purified factor B alone was added. Monocyte-mediated cytotoxicity induced by factor B was inhibited 73-100% by adding lymphocytes back to the purified monocytes. Thus, both lymphocytes and monocytes can serve as effector cells in this form of cytotoxicity but require cooperative interaction with different sets of complement components. In addition, lymphocytes can modulate the monocyte-mediated form of target cell lysis associated with factor B.
Assuntos
Enzimas Ativadoras do Complemento/imunologia , Proteínas do Sistema Complemento/imunologia , Citotoxicidade Imunológica , Linfócitos/imunologia , Monócitos/imunologia , Animais , Galinhas/sangue , Complemento C3/imunologia , Complemento C5/imunologia , Complemento C7/imunologia , Complemento C8/imunologia , Eritrócitos/imunologia , Cobaias , HumanosRESUMO
Factor D, when preincubated with platelet suspensions, at concentrations as low as 1.2 micrograms/ml, inhibited thrombin-induced platelet aggregation. No inhibition of collagen or arachidonic acid-induced platelet aggregation was found. Inhibition occurred, but to a lesser extent, when thrombin and factor D were added to platelets at the same time. No inhibition occurred when factor D was added after thrombin. Thrombin was able to overcome inhibition by factor D by increasing its concentration. Diisopropyl-phosphorofluoridate-inactivated factor D also inhibited thrombin-induced platelet aggregation so that enzymatic activity of factor D was not required for inhibition. Factor D absorbed with hirudin coupled to Sepharose 6B showed no decrease in inhibitory capacity. 125I-Factor D bound to platelets in a manner suggesting an equilibrium reaction similar to thrombin. At low factor D input, binding was linear, whereas at higher input, binding began to approach saturation. Binding of 125I-labeled thrombin to platelets was inhibited by factor D. Analysis of these data show that factor D does not alter the total number of thrombin molecules which bind to the platelet surface at saturation. However, the dissociation constant for thrombin is altered from 2.78 to 6.90 nM in the presence of factor D (20 micrograms/ml). Factor D is thus a competitive inhibitor of thrombin binding, although the affinity of factor D for the platelet thrombin receptor is much less than that of thrombin. These phenomena occur at physiologic concentrations of factor D. Therefore, factor D may function in vivo as an inhibitor of platelet aggregation.
Assuntos
Enzimas Ativadoras do Complemento/farmacologia , Fator D do Complemento/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Trombina/farmacologia , Ligação Competitiva , Plaquetas/metabolismo , Fator D do Complemento/metabolismo , Interações Medicamentosas , Hirudinas/farmacologia , Humanos , Técnicas In Vitro , Isoflurofato/farmacologia , Trombina/metabolismoRESUMO
Hereditary angioneurotic edema (HANE) results from deficiency of complement 1 inhibitor (C1 INH). In type I HANE, C1 INH is present in serum at levels 5-30% of normals. Using cultured monocytes and biosynthetic labeling of proteins, C1 INH was detected in supernatants of cells from HANE patients at levels 20% of those detected in normals. The intracellular reduction of C1 INH in patients' monocytes approached 50%. The study of C1 INH messenger RNA (mRNA) by Northern blot analysis indicated that in HANE patients' monocytes a message of normal size is present at about half the concentration of that from normal cells. One of the patients analyzed showed the presence of a genetically inherited abnormal mRNA (1.9 kb) in addition to the normal mRNA (2.1 kb). Southern blot analysis of DNA from peripheral blood leukocytes did not show any difference in quantity or in sizes of endonuclease restriction fragments between patients and normals. The defect(s), therefore, in type I HANE is pretranslational, but is not due to a deletion or to a major chromosomal rearrangement.
Assuntos
Angioedema/genética , Proteínas Inativadoras do Complemento 1/deficiência , Angioedema/sangue , Células Cultivadas , Proteínas Inativadoras do Complemento 1/sangue , Proteínas Inativadoras do Complemento 1/genética , DNA/genética , Humanos , Monócitos/metabolismo , Hibridização de Ácido Nucleico , RNA Mensageiro/metabolismoRESUMO
The molecular genetic basis of C1 inhibitor (C1 INH) deficiency in a patient with type I hereditary angioneurotic edema was studied. This patient was found to have an abnormally short C1 INH mRNA together with a normal message. Restriction fragment length polymorphism of the C1 INH gene was detected by Southern blot analysis of the patient's DNA after digestion with Pst I or Sac I, and hybridization with a full-length C1 INH cDNA. Hybridization of the same blot with three different fragments of the full-length cDNA suggested that exon VII and portions of both flanking introns were deleted in the C1 INH gene. Northern blot analysis of RNA from cultured monocytes, using a probe corresponding to exon VII, also indicated that the abnormal C1 INH mRNA had a deletion of these nucleotides. To confirm the hypothesis that the short C1 INH mRNA contained a deletion, the involved segment of the patient's C1 INH mRNA was amplified using the polymerase chain reaction (PCR). PCR amplification yielded two C1 INH DNA fragments of different lengths (380 and 160 bp). Southern blot and sequence analysis of both DNA fragments clearly revealed that the smaller 160-bp DNA was derived from the abnormal message and had a deletion of nucleotides corresponding to exon VII.
Assuntos
Angioedema/genética , Deleção Cromossômica , Proteínas Inativadoras do Complemento 1/deficiência , Éxons , RNA Mensageiro/genética , Sequência de Bases , Northern Blotting , Southern Blotting , Proteínas Inativadoras do Complemento 1/genética , DNA Polimerase Dirigida por DNA , Amplificação de Genes , Humanos , Íntrons , Dados de Sequência Molecular , Taq PolimeraseRESUMO
Members of two unrelated families with type I hereditary angioneurotic edema (HANE) were found to have elevated levels of C1 inhibitor (C1INH) mRNA. DNA sequence analysis of PCR-amplified monocyte C1INH mRNA revealed normal and mutant transcripts, as expected in this disorder that occurs in heterozygous individuals. Single base mutations near the 3' end of the coding sequence were identified in affected members of each family. One mutation consisted of insertion of an adenosine at position 1304 which created a premature termination codon (TAA), whereas the second consisted of deletion of the thymidine at position 1298 which created a premature termination codon (TGA) 23 nucleotides downstream. These mutations are approximately 250 nucleotides upstream of the natural termination codon. Nuclear run-off experiments in one kindred revealed no difference in transcription rates of the C1INH gene between the patients and normals. C1INH mRNA half-life experiments were not technically feasible because of the prolonged half-life of the normal transcript. Dideoxynucleotide primer extension experiments allowed the differentiation of the normal and mutant transcripts. These studies showed that the mutant transcript was not decreased relative to the normal, and this therefore was at least partially responsible for the C1INH mRNA elevation. This elevation may be due to the decreased catabolism of the mutant transcript.
Assuntos
Angioedema/genética , Proteínas Inativadoras do Complemento 1/genética , Mutação , RNA Mensageiro/análise , Sequência de Bases , Northern Blotting , Humanos , Reação em Cadeia da PolimeraseRESUMO
Patients with hereditary angioneurotic edema (HANE) have serum levels of functionally active inhibitor of the first component of complement (C1 INH) between 5 and 30% of normal, instead of the 50% expected from the single normal allele. Increases in rates of catabolism have been documented in patients with HANE and certainly account for some of decrease in C1 INH level. A possible role for a decrease in synthesis of C1 INH in producing serum levels of C1 INH below the expected 50% of normal has not been well studied. We studied the synthesis of C1 INH in skin fibroblast lines, which produce easily detectable amounts of C1 INH. In type I HANE cells, C1 INH synthesis was 19.6 +/- 4.0% (mean +/- SD) of normal, much less than the 50% predicted. In type II HANE cells, the total amount of C1 INH synthesis (functional and dysfunctional) was 98.9 +/- 17% of normal; the functional protein comprised 43% of the total. Thus, type II HANE cells synthesized functional C1 INH at a much greater rate than for the type I cells. In both type I and II HANE cells, amounts of steady-state C1 INH mRNA levels paralleled rates of C1 INH synthesis, indicating that control of C1 INH synthesis occurred at pretranslational levels. Both type I and type II fibroblasts synthesized normal amounts of C1r and C1s. These data suggest that the lower than expected amounts of functionally active C1 INH in type I HANE may be due, in part, to a decrease in rate of synthesis of the protein, and that the expressions of the normal C1 INH allele in HANE is influenced by the type of abnormal allele present.
Assuntos
Angioedema/metabolismo , Proteínas Inativadoras do Complemento 1/biossíntese , Adulto , Células Cultivadas , Fibroblastos/metabolismo , Humanos , Interferon gama/farmacologia , Monócitos/metabolismo , RNA Mensageiro/análiseRESUMO
We have determined the cause of an unusual C1 inhibitor abnormality in a large kindred. We previously found that half of serum C1 inhibitor molecules in affected kindred members are normal. The other half complexed with C1s but showed little complex formation with C1r. These molecules also appeared to be relatively resistant to digestion by trypsin. Taken together, the findings suggested that members of this kindred are heterozygous for an unusual C1 inhibitor mutation. Sequencing of genomic DNA from the kindred revealed that thymine has replaced cytosine in the codon for Ala443 (P2 residue) in one C1 inhibitor allele, resulting in substitution with a Val residue. To test the effect of this substitution, a mutant C1 inhibitor containing Ala443-->Val was constructed by site-directed mutagenesis and expressed in COS-1 cells. Both the Ala443-->Val mutant and the wild-type C1 inhibitor complexed completely with C1s, kallikrein, and coagulation Factor XIIa after incubation at 37 degrees C for 60 min. In contrast, the mutant inhibitor failed to complex completely with C1r under the same conditions. Time course analysis showed that the ability of the mutant to complex with C1s is also impaired: although it complexed completely in 60 min, the rate of complex formation during a 0-60-min incubation was decreased compared with wild-type C1 inhibitor. The mutant inhibitor also formed a complex with trypsin, a serine protease that cleaves, and is not inhibited by, wild-type C1 inhibitor. The Ala443-->Val mutation therefore converts C1 inhibitor from a substrate to an inhibitor of trypsin. These studies emphasize the role of the P2 residue in the determination of target protease specificity.
Assuntos
Proteínas Inativadoras do Complemento 1/genética , Mutação Puntual , Angioedema/classificação , Angioedema/diagnóstico , Angioedema/genética , Sequência de Bases , Proteínas Inativadoras do Complemento 1/metabolismo , Endopeptidases/metabolismo , Genes Dominantes/genética , Heterozigoto , Humanos , Lúpus Eritematoso Sistêmico/complicações , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Linhagem , Ligação Proteica , Desnaturação Proteica , Análise de Sequência de DNA , Tripsina/metabolismoRESUMO
The role of particle-bound complement proteins in the induction of noncytotoxic enzyme release from human granulocytes was investigated with the use of sera genetically deficient in complement and highly purified complement components. Release of histaminase, one of two important histamine catabolizing enzymes, and beta-glucuronidase from polymorphonuclear leukocytes was solely dependent on particle-bound C3b (the larger cleavage product of the third component of complement) when fluid-phase complement was excluded. The extent of enzyme release was a function of particle-bound C3b input, was reduced by exposing the particles to C3b inactivator, and was blocked by fluid-phase C3b. Phagocytosis of the C3b-coated particles was not required for enzyme release from neutrophils. In contrast, phagocytosis of "opsonized" particles was required for noncytotoxic release of histaminase and arylsulfatase from eosinophils; other proteins, as well as C3b, were able to opsonize particles for induction of enzyme release from eosinophils. These studies suggest a dual role for complement (particularly C3) in modulating vascular permeability phenomena, i.e., release of vasoactive mediators by the action of C3a and C5a, and release of the corresponding enzymes that inactivate the mediators by C3b.
Assuntos
Amina Oxidase (contendo Cobre)/metabolismo , Complemento C3b/fisiologia , Eosinófilos/enzimologia , Neutrófilos/enzimologia , Arilsulfatases/metabolismo , Glucuronidase/metabolismo , Humanos , Proteínas Opsonizantes , Fagocitose , ZimosanRESUMO
Hereditary angioneurotic edema (HANE) results from the deficiency of the inhibitor of the first component of human complement (C1-INH). It is inherited as an autosomal dominant trait. Heterogeneity of this defect has been shown at the protein and mRNA level. Southern blot analysis of genomic DNA was performed after digestion with six different restriction endonucleases in 24 families affected with type 1 HANE (low antigenic and functional C1-INH levels) and five with type 2 (low functional C1-INH levels and normal or elevated levels of dysmorphic C1-INH). Blots were hybridized with a C1-INH cDNA probe of 1,227 bp. With one enzyme (Pst I), two different patterns of restriction fragment length polymorphism (RFLP) were detected. One was present in one kindred with type 1 HANE and the other appeared the same in one type 1 and in one type 2 family, thus indicating that each RFLP resulted from a different mutation. Analysis of a total of 34 members of these three families suggested that the polymorphisms are tightly linked to the mutation responsible for the disease. Using a 170-bp probe we showed that the three different mutations leading to these polymorphisms are located in the same region of the C1-INH gene. These data suggest that different mutations in the same region of the C1-INH gene are responsible for C1-INH deficiency in these families. Most of these mutations are probably point mutations or other "minor" defects and do not appear to be due to major deletions or rearrangements.
Assuntos
Angioedema/genética , Proteínas Inativadoras do Complemento 1/genética , Genes , Polimorfismo Genético , Polimorfismo de Fragmento de Restrição , Humanos , Mutação , LinhagemRESUMO
Human monocytes synthesized the third component of complement (C3) up to 5 wk in vitro. Evidence for net C3 synthesis was based on (a) incorporation of 14C-labeled amino acids into C3 protein, (b) indentity of the allotype of C3 produced in vitro with that of the doner's serum C3, even in the presence of carrier C3 protein of a different allotype; (c) correspondence of electrophoretic mobility, size, and subunit structure of C3 protein produced in vitro with serum C3; (d) inhibition of C3 production with cycloheximide. Monocytes from two unrelated C3-deficient patients were studied under conditions that supported C3 synthesis by normal monocytes. Serum from each of the patients contained less than 1% of the normal C3 concentration, buth their monocytes produced C3 at approximately equal to 25% of the normal rate when studied after 2 wk in vitro. The C3 produced in vitro by monocytes from one of the patients had the molecular weight of normal serum C3 and dissociated appropriately under reducing conditions. Monocytes from C3-deficient patients could not be distinguished from normals on the basis of morphology, rosetting with C3-coated erythrocytes, or rates of C2, and total protein synthesis.
Assuntos
Complemento C3/biossíntese , Monócitos/metabolismo , Proteínas Sanguíneas/biossíntese , Células Cultivadas , Complemento C3/deficiência , Complemento C3/genética , Cicloeximida/farmacologia , Eletroforese em Gel de Ágar , Eletroforese em Gel de Poliacrilamida , Homozigoto , Humanos , Técnicas de Imunoadsorção , Monócitos/efeitos dos fármacosRESUMO
C1-inhibitor is a serine proteinase inhibitor that is active against C1s, C1r, kallikrein, and factor XII. Recently, it has been shown that it also has inhibitory activity against chymotrypsin. We have investigated this activity of normal human C1-inhibitor, normal rabbit C1-inhibitor, and P1 Arg to His mutant human C1-inhibitors and find that all are able to inhibit chymotrypsin and form stable sodium dodecyl sulfate-resistant complexes. The Kass values show that the P1 His mutant is a slightly better inhibitor of chymotrypsin than normal human C1-inhibitor (3.4 x 10(4) compared with 7.3 x 10(3)). The carboxy-terminal peptide of normal human C1-inhibitor, derived from the dissociated protease-inhibitor complex, shows cleavage between the P2 and P1 residues. Therefore, as with alpha 2-antiplasmin, C1-inhibitor possesses two overlapping P1 residues, one for chymotrypsin and the other for Arg-specific proteinases. In contrast, with the P1 His mutant, the peptide generated from the dissociation of its complex with chymotrypsin demonstrated cleavage between the P1 and P'1 residues. Therefore, unlike alpha 2-antiplasmin, chymotrypsin utilizes the P2 residue as its reactive site in normal C1-inhibitor but utilizes the P1 residue as its reactive site in the P1 His mutant protein. This suggests that the reactive center loop allows a degree of induced fit and therefore must be relatively flexible.
Assuntos
Quimotripsina/antagonistas & inibidores , Proteínas Inativadoras do Complemento 1/farmacologia , Sequência de Aminoácidos , Animais , Arginina , Sítios de Ligação , Proteínas Inativadoras do Complemento 1/genética , Histidina , Humanos , Dados de Sequência Molecular , Mutagênese , Fragmentos de Peptídeos , Coelhos , Proteínas Recombinantes/farmacologia , Análise de Sequência , Homologia de Sequência de AminoácidosRESUMO
A P1 mutation (Arg-444-->Leu) was identified in a dysfunctional C1 inhibitor from a patient with type 2 hereditary angioneurotic edema. The mutation was defined at the level of the protein (by sequence analysis of the Pseudomonas aeruginosa elastase-derived reactive center peptide), and the mRNA (CGC-->CTC) (by sequence analysis of PCR-amplified DNA).
Assuntos
Angioedema/genética , Proteínas Inativadoras do Complemento 1/genética , Serpinas/genética , Sequência de Aminoácidos , Arginina , Sítios de Ligação/genética , Humanos , Leucina , Dados de Sequência Molecular , Mutação , Fragmentos de Peptídeos/genética , Reação em Cadeia da Polimerase , Relação Estrutura-AtividadeRESUMO
Three protein-deficient diets containing 5%, 6%, or 7% casein, with and without 0.3% methionine supplementation, were fed to Wistar rats from weaning for 6 wk. Animals were infected subcutaneously with 1500 larvae of Nippostrongylus brasiliensis and killed after 14 days when nutritionally normal animals have expelled more than 97% of the worm burden. There was a delay in worm expulsion that was related to both the protein content (p = 0.0006) and to methionine content (p less than 0.0001). Methionine supplementation significantly reduced the worm burden in animals fed the 7% protein diet from a geometric mean of 32.4 to 5.2 (p = 0.0408) and in rats fed the 6% protein diet from a mean of 162 to 8.1 (p = 0.0002) but had no effect in rats on the 5% casein diet. Thus, addition of methionine overcame the adverse effect of protein deficiency in these less severely affected groups.
Assuntos
Metionina/deficiência , Infecções por Nematoides/imunologia , Deficiência de Proteína/imunologia , Animais , Peso Corporal , Dieta , Intestino Delgado/parasitologia , Masculino , Metionina/administração & dosagem , Nippostrongylus , Ratos , Ratos Endogâmicos , Albumina Sérica/metabolismoRESUMO
Rats on a low protein diet, containing 10% casein as the only source of protein, have an impaired capacity to expel primary infections with the nematode Nippostrongylus brasiliensis and remain susceptible to reinfection. In the present study, the transfer of syngeneic bone marrow cells to rats on a low protein diet reconstituted the expulsion mechanism allowing parasite rejection to occur at the same rate as rats on a sufficient diet. Serum transfer, on the other hand, did not significantly alter the rate of worm expulsion. These results demonstrate that a bone marrow derived component plays an important role in the impaired immunity of rats fed a low protein diet.
Assuntos
Transplante de Medula Óssea , Proteínas Alimentares/administração & dosagem , Infecções por Nematoides/terapia , Animais , Sangue , Medula Óssea/imunologia , Células da Medula Óssea , Soros Imunes , Nippostrongylus , Deficiência de Proteína/imunologia , Ratos , Transplante IsogênicoRESUMO
Fifty-nine patients who had duodenal ulcers that were healed following sucralfate administration in a dose of 1 g four times a day were randomly entered into a double-blind, placebo-controlled, 12-month maintenance study to determine whether sucralfate 1 g twice daily prevents recurrence of duodenal ulceration. Patients were assessed endoscopically at four, eight, and 12 months after healing or earlier if clinical relapse occurred. Of the original 59 patients, 53 showed healing with six weeks of therapy, and the remaining six patients required 10 weeks of treatment. Nine patients were subsequently lost to follow-up because of non-compliance, leaving 50 patients for the analysis, 24 who received sucralfate and 26 who received placebo. There were 10 ulcer recurrences in the sucralfate group and the ulcers in 14 (58 percent) patients remaining healed at the end of 12 months. In contrast, there were 21 recurrences in the placebo group with the ulcers in five patients (19 percent) remaining healed at 12 months. Patients who received placebo experienced recurrence more quickly than those who received sucralfate and there was no difference between the two groups in terms of symptomatic and asymptomatic recurrence. There was no alteration in serum aluminium and phosphate levels throughout the study. Smoking seemed to have no adverse effect on recurrence once initial healing had been achieved. Sucralfate is, therefore, an effective and safe maintenance treatment for duodenal ulcer disease.
Assuntos
Úlcera Duodenal/prevenção & controle , Sucralfato/uso terapêutico , Alumínio/sangue , Avaliação de Medicamentos , Úlcera Duodenal/sangue , Úlcera Duodenal/patologia , Duodenoscopia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fosfatos/sangue , Distribuição Aleatória , Sucralfato/administração & dosagemRESUMO
Two patients with a persistent mesangial proliferative glomerulonephritis and reduced serum C3 levels have been followed for six and 10 years. Both have had a mild course with normal renal function and spontaneous morphologic improvement. Levels of the fourth component (C4) and second component (C2) of complement, and properdin factor B have been normal; the third component (C3) of complement nephritic factor has not been detected. Ultrastructurally, irregular intramembranous electron-dense deposits are present, primarily within the lamina densa. These deposits are separated by varying lengths of normal-appearing glomerular basement membrane. Intramembranous and subendothelial electron-lucent areas, containing vesicles, are also seen. Subendothelial deposits, mesangial interposition, splitting of the glomerular basement membrane and ribbon-like intramembranous deposits are not found. The disease in these patients was clinically indistinguishable at onset from mrmbranoproliferative glomerulonephritis (MPGN). The possibility of a variant with mild clinical course, no progression and spontaneous morphologic improvement is important in planning and assessing treatment programs in this disease group.
Assuntos
Proteínas do Sistema Complemento/metabolismo , Glomerulonefrite/imunologia , Adolescente , Membrana Basal/ultraestrutura , Capilares/ultraestrutura , Complemento C3/metabolismo , Feminino , Imunofluorescência , Glomerulonefrite/patologia , Humanos , Glomérulos Renais/irrigação sanguínea , Glomérulos Renais/ultraestruturaRESUMO
Antigen B, a major antigen of the cestode parasite Taenia solium, has been purified and a portion of amino acid sequence obtained. Paramyosin of the trematode parasite Schistosoma mansoni, an immunogenic protein that has shown promise as a vaccine candidate, has several biochemical and immunological properties in common with antigen B. A full-length cDNA clone of S. mansoni paramyosin has been obtained and the predicted translation product contains a sequence that is highly homologous to the sequence obtained for antigen B. The predicted amino acid composition and isolectric point of paramyosin are nearly identical to those established for antigen B. Recombinant S. mansoni paramyosin, expressed in Escherichia coli as a fusion protein with beta-galactosidase, was recognized by antisera against T. solium antigen B. We conclude from these results that S. mansoni paramyosin and T. solium antigen B are homologous proteins. Since S. mansoni paramyosin is thought to be a muscle protein and T. solium antigen B a secreted glycoprotein with anti-complement activity, this conclusion raises some interesting questions regarding the role of this class of proteins in the host-parasite relationship.